Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) and BeOne Medicines (NASDAQ:ONC – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
Profitability
This table compares Sunshine Biopharma and BeOne Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sunshine Biopharma | -17.94% | -26.36% | -20.60% |
| BeOne Medicines | 10.70% | 14.23% | 7.82% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Sunshine Biopharma and BeOne Medicines, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sunshine Biopharma | 1 | 1 | 1 | 0 | 2.00 |
| BeOne Medicines | 1 | 1 | 12 | 3 | 3.00 |
Risk and Volatility
Sunshine Biopharma has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
Valuation and Earnings
This table compares Sunshine Biopharma and BeOne Medicines”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sunshine Biopharma | $36.31 million | 0.12 | -$5.97 million | ($10.15) | -0.11 |
| BeOne Medicines | $5.34 billion | 7.36 | $286.93 million | $5.68 | 63.07 |
BeOne Medicines has higher revenue and earnings than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are owned by institutional investors. 0.5% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
BeOne Medicines beats Sunshine Biopharma on 13 of the 15 factors compared between the two stocks.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
